|
Sep 26
|
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
|
|
Sep 9
|
Theratechnologies to Present at Upcoming Investor Conferences in September
|
|
Aug 26
|
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
|
|
Jul 16
|
Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
|
|
Jul 16
|
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
|
|
Jun 26
|
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
|
|
May 9
|
Theratechnologies Reports on its Annual Meeting of Shareholders
|
|
May 2
|
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
|
|
Apr 23
|
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Apr 15
|
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
|
|
Apr 11
|
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
|
Apr 10
|
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
|
|
Apr 8
|
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
|
|
Apr 5
|
Theratechnologies Appoints Elina Tea to its Board of Directors
|
|
Apr 3
|
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
|
|
Mar 28
|
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
|
|
Mar 22
|
Theratechnologies Announces Update on its Preclinical Oncology Research Program
|
|
Mar 22
|
Theratechnologies Appoints Jordan Zwick to its Board of Directors
|
|
Mar 21
|
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|
|
Jan 2
|
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
|